We are the only research platform leveraging the award-winning PhyloChip® assay developed at the Lawrence Berkeley National Laboratory. This technology is capable of providing the most detailed measurements of microbial community dynamics in a high-throughput reproducible manner.
We routinely employ highly parallel sequencing assay for conducting 16S community analysis as an initial step in our exploratory discovery. This method allows classification of both known and unknown bacteria to conduct comparative analysis between the relative abundance of bacterial and archaeal species.
This technology goes beyond 16S rRNA microbial abundance and diversity determination to provide valuable insight into the functional gene composition of the microbial community. This advanced investigation utilizes specialized methods in both sequencing and bioinformatics to provide critical information on the function and pathways encoded in the microbiome.
Characterizing both the pathways and specific functions expressed by the microbes in an environment, this technology provides the most robust approach for exploring microbial function. Leveraging this technology we are able to uncover the functions required for a microbial community to survive, and when used in comparative analysis it can identify key functions and pathways that differentiate one community from another.
This technology provides another datapoint from 16S community profiles to estimate the metagenomic function of a microbial community. In this computational approach to functional composition, 16S sequencing reads are mapped to known genome’s within a reference database to give initial insight into the function of differentiated taxa.
Our informatics team integrates the data across multiple microbiome technologies and multiple cohorts. We call this procedure Multi-Tech Meta-Analysis (MTMA) and it allows us to determine the specific strains and their expressed bioactive molecules within the diseased or healthy tissues. These proteins and metabolites can be assayed directly for therapeutic properties or indirectly to identify drug targets in the patients.